Role of ischemia-modified albumin in clinical practice
[ X ]
Tarih
2015
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Walter de Gruyter GmbH
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Difficulty in establishing a diagnosis of acute coronary syndrome (ACS) in the clinical setting has led researchers to investigate novel markers that show increased blood levels before the myocardial necrosis occurs. In ischemic conditions, some modifications occur in the amino acids located on the N-terminus of the human albumin molecule. Ischemia-modified albumin (IMA) is a marker formed after damage in the N-terminal region of albumin. The altered N-terminus can no longer bind transition metals, such as cobalt. The causes of the increases in IMA have been shown to be endothelial or extracellular hypoxia, acidosis, and free oxygen radicals. IMA, an early marker of ischemic disorders, is also a candidate marker for the detection of ACS. An assay measuring IMA might represent a promising marker for the identification of patients with myocardial ischemia. The aim of this study was to evaluate the clinical utility of IMA in the assessment of ACS as well as other medical disorders in light of the recent literature. © 2015 by De Gruyter.
Açıklama
Anahtar Kelimeler
Acute Coronary Syndrome, Biochemistry, Ischemia-Modified Albumin
Kaynak
LaboratoriumsMedizin
WoS Q Değeri
N/A
Scopus Q Değeri
N/A
Cilt
39
Sayı
4
Künye
Erenler, A. K., Yardan, T., Katı, C., Altuntaş, M., Türedi, S. (2015). Role of ischemia-modified albumin in clinical practice. LaboratoriumsMedizin, 39(4), 241-247.
